Abbott Laboratories Company Profile (NYSE:ABT)

About Abbott Laboratories (NYSE:ABT)

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Industry, Sector and Symbol:

Sector: Medical
Industry: Pharmaceuticals
Sub-Industry: Health Care Equipment
Symbol: NYSE:ABT
CUSIP: 00282410
Web: www.abbott.com

Capitalization:

Market Cap: $89.3567 billion
Outstanding Shares: 1,737,443,000

Average Prices:

50 Day Moving Avg: $50.14
200 Day Moving Avg: $47.04
52 Week Range: $37.38 - $52.60

P/E:

Trailing P/E Ratio: 73.54
Foreward P/E Ratio: 18.82
P/E Growth: 1.83

Sales & Book Value:

Annual Revenue: $23.61 billion
Price / Sales: 3.86
Book Value: $18.19 per share
Price / Book: 2.89

Dividend:

Annual Dividend: $1.06
Dividend Yield: 2.1%

Profitability:

EBIDTA: $5.14 billion
Net Margins: 4.96%
Return on Equity: 14.43%
Return on Assets: 6.47%

Debt:

Debt-to-Equity Ratio: 0.75%
Current Ratio: 2.94%
Quick Ratio: 2.41%

Misc:

Average Volume: 5.27 million shs.
Beta: 1.06
Short Ratio: 2.35

Frequently Asked Questions for Abbott Laboratories (NYSE:ABT)

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Friday, September 15th. Investors of record on Friday, October 13th will be paid a dividend of $0.265 per share on Wednesday, November 15th. This represents a $1.06 annualized dividend and a dividend yield of 2.02%. The ex-dividend date is Thursday, October 12th. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) announced its quarterly earnings data on Thursday, July, 20th. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.60 by $0.02. The firm had revenue of $6.64 billion for the quarter, compared to the consensus estimate of $6.63 billion. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The business's revenue was up 24.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.55 earnings per share. View Abbott Laboratories' Earnings History.

When will Abbott Laboratories make its next earnings announcement?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, October, 18th 2017. View Earnings Estimates for Abbott Laboratories.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories issued an update on its third quarter earnings guidance on Thursday, July, 20th. The company provided earnings per share guidance of $0.64-0.66 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.66. Abbott Laboratories also updated its FY17 guidance to $2.43-2.53 EPS.

Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2017?

12 brokers have issued 12 month price objectives for Abbott Laboratories' shares. Their forecasts range from $42.00 to $58.00. On average, they expect Abbott Laboratories' stock price to reach $53.25 in the next twelve months. View Analyst Ratings for Abbott Laboratories.

Who are some of Abbott Laboratories' key competitors?

Some companies that are related to Abbott Laboratories include Sanofi (SNY), Novo Nordisk A/S (NVO), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Catalent (CTLT), Patheon NV (PTHN), Valeant Pharmaceuticals International (VRX), Taro Pharmaceutical Industries (TARO), Akorn (AKRX) and Opko Health (OPK).

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:

Miles D. White, Chairman of the Board, Chief Executive Officer
Brian B. Yoor, Chief Financial Officer, Senior Vice President - Finance
Michael T. Rousseau, President - Cardiovascular and Neuromodulation
Hubert L. Allen, Executive Vice President, General Counsel, Secretary
Stephen R. Fussell, Executive Vice President - Human Resources
Brian J. Blaser, Executive Vice President - Diagnostics Products
John M. Capek Ph.D., Executive Vice President - Ventures
Robert B. Ford, Executive Vice President - Medical Devices
Heather L. Mason, Executive Vice President - Nutritional Products
Roger Bird, Senior Vice President - U.S. Nutrition

Who owns Abbott Laboratories stock?

Abbott Laboratories' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.48%), BlackRock Inc. (6.01%), State Street Corp (4.43%), Capital Research Global Investors (2.74%), Bank of New York Mellon Corp (1.94%) and Northern Trust Corp (1.55%). Company insiders that own Abbott Laboratories stock include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?

Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Fort Washington Investment Advisors Inc. OH, FMR LLC, Macquarie Group Ltd., BlackRock Inc., Prudential PLC and DnB Asset Management AS. Company insiders that have sold Abbott Laboratories stock in the last year include Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jared Watkin, Joseph J Manning, Michael J Warmuth, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?

Abbott Laboratories' stock was purchased by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Janus Henderson Group PLC, Vanguard Group Inc., Dimensional Fund Advisors LP, Boston Partners, Principal Financial Group Inc., Parametric Portfolio Associates LLC and Hexavest Inc.. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.

How do I buy Abbott Laboratories stock?

Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of Abbott Laboratories stock can currently be purchased for approximately $52.51.

MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		564 (Vote Outperform)
Underperform Votes:		414 (Vote Underperform)
Total Votes:		978

MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Abbott Laboratories (NYSE:ABT) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	4 Hold Ratings, 8 Buy Ratings
Consensus Rating:	Buy (Score: 2.67)
Consensus Price Target:	$53.25 (1.41% upside)

Analysts' Ratings History for Abbott Laboratories (NYSE:ABT)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
9/1/2017	BMO Capital Markets	Reiterated Rating	Hold	$53.00	N/A
8/17/2017	Citigroup Inc.	Initiated Coverage	Neutral -> Neutral	$53.00	Medium
8/17/2017	Cowen and Company	Reiterated Rating	Buy	$55.00	Medium
8/3/2017	Jefferies Group LLC	Reiterated Rating	Buy	$58.00	Low
7/22/2017	Barclays PLC	Reiterated Rating	Overweight	$52.00 -> $57.00	Low
7/21/2017	Stifel Nicolaus	Reiterated Rating	Buy	$58.00	Low
7/10/2017	Morgan Stanley	Reiterated Rating	Equal Weight		Low
6/30/2017	Wells Fargo & Company	Reiterated Rating	Outperform	$47.50 -> $54.00	Low
6/29/2017	Guggenheim	Initiated Coverage	Buy	$58.00	Low
6/21/2017	BTIG Research	Initiated Coverage	Buy	$56.00	Low
5/16/2017	Goldman Sachs Group, Inc. (The)	Initiated Coverage	Neutral -> Neutral	$45.00	Low
5/15/2017	Royal Bank Of Canada	Reiterated Rating	Buy		Low
9/19/2016	Bank of America Corporation	Reiterated Rating	Buy		N/A
8/9/2016	Deutsche Bank AG	Reiterated Rating	Buy		N/A
7/28/2016	Argus	Reiterated Rating	Buy	$55.00	N/A
6/21/2016	Edward Jones	Upgrade	Hold -> Buy		N/A
6/8/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A
4/30/2016	S&P Equity Research	Reiterated Rating	Hold		N/A
4/30/2016	Gabelli	Reiterated Rating	Buy		N/A
4/28/2016	Piper Jaffray Companies	Downgrade	Overweight -> Neutral		N/A
4/14/2016	First Global	Downgrade	Outperform -> Marketperform		N/A
3/28/2016	Leerink Swann	Boost Price Target	Market Perform	$37.00 -> $40.00	N/A
1/29/2016	Raymond James Financial, Inc.	Lower Price Target	Outperform	$46.00 -> $42.00	N/A
1/29/2016	William Blair	Downgrade	Outperform -> Market Perform		N/A

(Data available from 9/23/2015 forward)

Earnings History for Abbott Laboratories (NYSE:ABT)

Earnings by Quarter for Abbott Laboratories (NYSE:ABT)

Earnings History by Quarter for Abbott Laboratories (NYSE ABT)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/18/2017		$0.66					N/A
7/20/2017	Q2 2017	$0.60	$0.62	$6.63 billion	$6.64 billion	View	N/A
4/19/2017	3/31/2017	$0.43	$0.48	$6.16 billion	$6.34 billion	View	N/A
1/25/2017	Q416	$0.64	$0.65	$5.41 billion	$5.33 billion	View	Listen
10/19/2016	Q316	$0.58	$0.59	$5.29 billion	$5.30 billion	View	Listen
7/20/2016	Q216	$0.53	$0.55	$5.24 billion	$5.30 billion	View	Listen
4/20/2016	Q116	$0.39	$0.41	$4.77 billion	$4.90 billion	View	Listen
1/28/2016	Q415	$0.61	$0.62	$5.31 billion	$5.20 billion	View	Listen
10/21/2015	Q315	$0.53	$0.54	$5.16 billion	$5.15 billion	View	Listen
7/22/2015	Q215	$0.50	$0.52	$5.15 billion	$5.20 billion	View	Listen
4/22/2015	Q115	$0.42	$0.47	$4.85 billion	$4.90 billion	View	Listen
1/29/2015	Q414	$0.68	$0.71	$5.48 billion	$5.36 billion	View	Listen
10/22/2014	Q314	$0.60	$0.62	$5.62 billion	$5.10 billion	View	Listen
7/16/2014	Q214	$0.51	$0.54	$5.53 billion	$5.55 billion	View	Listen
4/16/2014	Q114	$0.36	$0.41	$5.29 billion	$5.24 billion	View	Listen
1/22/2014	Q413	$0.58	$0.58	$5.72 billion	$5.66 billion	View	Listen
10/16/2013	Q313	$0.52	$0.55	$5.46 billion	$5.37 billion	View	Listen
7/17/2013	Q2 2013	$0.44	$0.46	$5.53 billion	$5.45 billion	View	Listen
4/17/2013	Q1 2013	$0.41	$0.42	$5.42 billion	$5.38 billion	View	Listen
1/23/2013	Q4 2012	$1.50	$1.51	$10.58 billion	$10.80 billion	View	Listen
10/17/2012		$1.28	$1.30			View	N/A
7/18/2012		$1.22	$1.23			View	N/A
4/18/2012		$1.00	$1.03			View	N/A
1/25/2012		$1.44	$1.45			View	N/A
10/19/2011		$1.17	$1.18			View	N/A
7/20/2011		$1.12	$1.12			View	N/A
4/20/2011		$0.90	$0.91			View	N/A
1/26/2011		$1.29	$1.30			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Abbott Laboratories (NYSE:ABT)

2017 EPS Consensus Estimate: $2.44
2018 EPS Consensus Estimate: $2.83

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	3	$0.43	$0.50	$0.45
Q2 2017	3	$0.59	$0.61	$0.60
Q3 2017	3	$0.64	$0.68	$0.66
Q4 2017	3	$0.72	$0.73	$0.73
Q1 2018	2	$0.55	$0.56	$0.56
Q2 2018	2	$0.69	$0.71	$0.70
Q3 2018	2	$0.74	$0.76	$0.75
Q4 2018	2	$0.80	$0.84	$0.82

(Data provided by Zacks Investment Research)

Current Dividend Information for Abbott Laboratories (NYSE:ABT)

Next Dividend:	11/15/2017
Annual Dividend:	$1.06
Dividend Yield:	2.02%
Dividend Growth:	22.90% (3 Year Average)
Payout Ratio:	149.30% (Trailing 12 Months of Earnings) 42.57% (Based on This Year's Estimates) 37.99% (Based on Next Year's Estimates)
Track Record:	44 Years of Consecutive Dividend Growth

Dividend Payments by Quarter for Abbott Laboratories (NYSE:ABT)

Dividend History by Quarter for Abbott Laboratories (NYSE ABT)

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/15/2017	quarterly	$0.27	2.05%	10/12/2017	10/13/2017	11/15/2017
6/9/2017	quarterly	$0.27	2.25%	7/12/2017	7/14/2017	8/15/2017
2/17/2017	quarterly	$0.27	2.36%	4/11/2017	4/14/2017	5/15/2017
12/9/2016	quarterly	$0.27	2.7%	1/11/2017	1/13/2017	2/15/2017
9/15/2016	quarterly	$0.26	2.48%	10/12/2016	10/14/2016	11/15/2016
6/10/2016	quarterly	$0.26	2.75%	7/13/2016	7/15/2016	8/15/2016
2/19/2016	quarterly	$0.26	2.66%	4/13/2016	4/15/2016	5/16/2016
12/11/2015	quarterly	$0.26	2.32%	1/13/2016	1/15/2016	2/16/2016
9/17/2015	quarterly	$0.24	2.22%	10/13/2015	10/15/2015	11/15/2015
6/12/2015	quarterly	$0.24	2%	7/13/2015	7/15/2015	8/15/2015
2/20/2015	quarterly	$0.24	2.03%	4/13/2015	4/15/2015	5/15/2015
12/12/2014	quarterly	$0.24	2.21%	1/13/2015	1/15/2015	2/13/2015
9/11/2014	quarterly	$0.22	2.07%	10/10/2014	10/15/2014	11/15/2014
6/13/2014	quarterly	$0.22	2.21%	7/11/2014	7/15/2014	8/15/2014
2/21/2014	quarterly	$0.22	2.26%	4/11/2014	4/15/2014	5/15/2014
10/16/2013	quarterly	$0.22	2.37%	1/13/2014	1/15/2014	2/15/2014
9/12/2013	quarterly	$0.14	1.61%	10/10/2013	10/15/2013	11/15/2013
6/14/2013	quarterly	$0.14	1.52%	7/11/2013	7/15/2013	8/15/2013
2/15/2013	quarterly	$0.14	1.61%	4/11/2013	4/15/2013	5/15/2013
12/14/2012	quarterly	$0.14	0.86%	1/11/2013	1/15/2013	2/15/2013

(Data available from 1/1/2013 forward)

Insider Trading and Institutional Ownership History for Abbott Laboratories (NYSE:ABT)

Insider Ownership Percentage: 0.76%
Institutional Ownership Percentage: 71.50%

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/16/2017	Stephen R Fussell	Insider	Sell	196,550	$49.50	$9,729,225.00
8/1/2017	Sharon J Bracken	Insider	Sell	2,000	$49.16	$98,320.00
7/27/2017	Brian J Blaser	Insider	Sell	15,000	$50.00	$750,000.00
7/25/2017	Hubert L Allen	Insider	Sell	4,600	$50.79	$233,634.00
6/15/2017	Jared Watkin	Insider	Sell	552	$47.97	$26,479.44
6/8/2017	Stephen R Fussell	Insider	Sell	196,550	$46.00	$9,041,300.00
4/27/2017	Roger Bird	Insider	Sell	5,600	$43.82	$245,392.00
4/26/2017	Joseph J Manning	Insider	Sell	4,200	$43.95	$184,590.00
3/1/2017	Michael J. Warmuth	Insider	Sell	3,851	$45.39	$174,796.89
2/23/2017	Robert E Funck	VP	Sell	25,500	$45.50	$1,160,250.00
2/22/2017	Roger Bird	Insider	Sell	13,222	$45.02	$595,254.44
2/21/2017	Deepak S Nath	Insider	Sell	319	$44.98	$14,348.62
1/31/2017	Heather L Mason	Insider	Sell	35,700	$40.77	$1,455,489.00
12/20/2016	Brian J Blaser	Insider	Buy	15,580	$38.45	$599,051.00
12/14/2016	Robert B Ford	Insider	Buy	12,775	$39.09	$499,374.75
11/10/2016	Miles D White	Chairman	Buy	121,456	$40.45	$4,912,895.20
11/1/2016	Sally E Blount	Director	Buy	5,100	$39.24	$200,124.00
9/26/2016	Daniel Gesua Sive Salvadori	SVP	Sell	815	$41.71	$33,993.65
7/28/2016	Stephen R Fussell	Insider	Sell	41,500	$45.00	$1,867,500.00
7/26/2016	Michael J Warmuth	Insider	Sell	26,800	$43.49	$1,165,532.00
7/25/2016	Miles D White	Chairman	Buy	242,547	$43.18	$10,473,179.46
7/25/2016	Robert E Funck	VP	Sell	26,800	$43.08	$1,154,544.00
6/28/2016	Hubert L Allen	EVP	Sell	3,400	$37.14	$126,276.00
6/15/2016	Jared Watkin	SVP	Sell	552	$37.63	$20,771.76
6/1/2016	Brian B Yoor	CFO	Sell	565	$39.49	$22,311.85
4/28/2016	Deepak S Nath	SVP	Sell	53	$41.31	$2,189.43
3/31/2016	Jaime Contreras	SVP	Sell	462	$41.78	$19,302.36
2/29/2016	Brian B Yoor	CFO	Sell	865	$39.12	$33,838.80
2/29/2016	Deepak S Nath	SVP	Sell	793	$39.27	$31,141.11
2/29/2016	Robert B Ford	EVP	Sell	1,706	$39.28	$67,011.68
2/29/2016	Robert E Funck	VP	Sell	1,333	$39.30	$52,386.90
2/22/2016	Jared Watkin	SVP	Sell	554	$39.09	$21,655.86
2/16/2016	Deepak S. Nath	SVP	Sell	171	$37.13	$6,349.23
12/16/2015	Miles D. White	CEO	Sell	438,000	$46.00	$20,148,000.00
8/18/2015	Stephen R. Fussell	EVP	Sell	13,096	$50.46	$660,824.16
4/27/2015	Heather L Mason	EVP	Sell	13,500	$47.45	$640,575.00
4/27/2015	Roger Bird	SVP	Sell	28,548	$47.57	$1,358,028.36
3/26/2015	J. Scott White	SVP	Sell	12,483	$46.68	$582,706.44
3/2/2015	Jaime Contreras	SVP	Sell	9,209	$47.34	$435,954.06
2/4/2015	John M Capek	EVP	Sell	34,292	$45.66	$1,565,772.72
11/25/2014	Jaime Contreras	SVP	Sell	51,600	$44.07	$2,274,012.00
10/29/2014	Miles D White	CEO	Sell	440,800	$42.52	$18,742,816.00
3/3/2014	John Landgraf	EVP	Sell	17,293	$39.38	$680,998.34
3/3/2014	Katherine Doyle	SVP	Sell	6,639	$39.01	$258,987.39
3/3/2014	Robert Funck	VP	Sell	1,413	$38.97	$55,064.61
2/18/2014	John Landgraf	EVP	Sell	1,583	$39.10	$61,895.30
1/29/2014	Michael Warmuth	EVP	Sell	11,430	$36.21	$413,880.30
12/6/2013	Jean-Yves Pavee	SVP	Sell	5,855	$37.46	$219,328.30
11/7/2013	Stephen Fussell	EVP	Sell	10,466	$37.59	$393,416.94
10/30/2013	Jaime Contreras	SVP	Sell	25,368	$36.85	$934,810.80
6/7/2013	Heather L Mason	SVP	Sell	12,000	$37.01	$444,120.00
2/1/2013	William A Osborn	Director	Buy	10,000	$33.86	$338,600.00

(Data available from 1/1/2013 forward)

Headline Trends for Abbott Laboratories (NYSE:ABT) Latest Headlines for Abbott Laboratories (NYSE:ABT)

Source:

Date	Headline
	Abbott Secures FDA Approval for MRI-Compatibility for the Company's Ellipse™ ICD finance.yahoo.com - September 22 at 12:20 PM
	Here's Why You Should Add Abbott (ABT) to Your Portfolio Now finance.yahoo.com - September 22 at 12:20 PM
	Abbott Laboratories (ABT) Lifted to Buy at Zacks Investment Research www.americanbankingnews.com - September 22 at 11:30 AM
	Abbott Hosts Conference Call for Third-Quarter Earnings finance.yahoo.com - September 20 at 3:18 PM
	Buy Abbott Laboratories - Cramer's Lightning Round (9/15/17) - Seeking Alpha seekingalpha.com - September 18 at 8:35 PM
	IWB, SLB, ABT, UNP: Large Outflows Detected at ETF www.nasdaq.com - September 18 at 3:33 PM
	Abbott Laboratories’ 375th Consecutive Quarterly Dividend finance.yahoo.com - September 18 at 3:33 PM
	Abbott Laboratories (ABT) Expected to Post Quarterly Sales of $6.71 Billion www.americanbankingnews.com - September 18 at 9:40 AM
	Abbott Laboratories (ABT) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - September 17 at 9:02 AM
	Zacks: Brokerages Anticipate Abbott Laboratories (ABT) to Post $0.65 Earnings Per Share www.americanbankingnews.com - September 16 at 6:12 AM
	Alibaba, Qorvo, Abbott Laboratories, Square: 'Mad Money' Lightning Round - TheStreet.com www.thestreet.com - September 15 at 11:41 PM
	Abbott Laboratories (ABT) Announces Quarterly Dividend of $0.27 www.americanbankingnews.com - September 15 at 5:52 PM
	Head-To-Head Contrast: Abbott Laboratories (ABT) versus Its Peers www.americanbankingnews.com - September 14 at 8:28 PM
	Abbott Declares 375th Consecutive Quarterly Dividend finance.yahoo.com - September 14 at 3:19 PM
	FreeStyle® Libre Flash Glucose Monitoring Technology Gains Reimbursement Approval from the United Kingdom's National Health Service finance.yahoo.com - September 14 at 1:33 AM
	3 Big Stock Charts for Tuesday: Abbott Laboratories (ABT), Aetna Inc (AET) and Boston Scientific Corporation (BSX) - Investorplace.com investorplace.com - September 12 at 3:23 PM
	Can Abbott Top Its All-Time High? seekingalpha.com - September 7 at 8:20 PM
	Abbott (ABT) Hits a 52-Week High: What's Driving the Stock? finance.yahoo.com - September 7 at 3:19 PM
	Abbott Named Industry Leader for Responsible and Sustainable Business for Five Consecutive Years on the Dow Jones Sustainability Index (DJSI) finance.yahoo.com - September 7 at 3:19 PM
	ETFs with exposure to Abbott Laboratories : September 7, 2017 finance.yahoo.com - September 7 at 3:19 PM
	Abbott Laboratories :ABT-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017 finance.yahoo.com - September 5 at 3:29 PM
	Abbott Laboratories (ABT) Stock Rating Reaffirmed by BMO Capital Markets www.americanbankingnews.com - September 2 at 10:38 AM
	Abbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod - Nasdaq www.nasdaq.com - September 1 at 3:44 PM
	Abbott's AMPLATZER Pivotal Study to Strengthen Vascular Arm finance.yahoo.com - September 1 at 3:44 PM
	Abbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod finance.yahoo.com - September 1 at 3:44 PM
	Revolutionary Glucose Monitoring Technology FreeStyle® Libre Now Reimbursed Across Japan finance.yahoo.com - August 31 at 3:20 PM
	Abbott Updates Pacemaker, Defibrillator Software to Protect Against Hacking - TheStreet.com www.thestreet.com - August 30 at 8:24 PM
	Abbott software updates aim to fix pacemaker battery issues, hacking risks www.marketwatch.com - August 30 at 3:22 PM
	Abbott Updates Pacemaker, Defibrillator Software to Protect Against Hacking finance.yahoo.com - August 30 at 3:21 PM
	Abbott initiates ground-breaking U.S. pivotal study of AMPLATZER device to correct common congenital heart defect in newborns finance.yahoo.com - August 30 at 3:21 PM
	Abbott Laboratories (ABT) Expected to Announce Quarterly Sales of $6.71 Billion www.americanbankingnews.com - August 30 at 5:34 AM
	Abbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm - Nasdaq www.nasdaq.com - August 29 at 8:46 PM
	Analysts’ Recommendations for Pfizer in August 2017 finance.yahoo.com - August 29 at 8:46 PM
	Abbott Releases New Software Updates for Pacemakers finance.yahoo.com - August 29 at 8:46 PM
	Top Momentum Picks In Blue-Chip Health Care seekingalpha.com - August 29 at 3:45 PM
	Top Momentum Picks In Blue-Chip Health Care seekingalpha.com - August 29 at 3:45 PM
	Abbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm www.zacks.com - August 29 at 3:45 PM
	Abbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm www.zacks.com - August 29 at 3:45 PM
	Abbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm finance.yahoo.com - August 29 at 3:45 PM
	Abbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm finance.yahoo.com - August 29 at 3:45 PM
	Abbott releases new round of cyber updates for St. Jude pacemakers finance.yahoo.com - August 29 at 3:45 PM
	Abbott releases new round of cyber updates for St. Jude pacemakers finance.yahoo.com - August 29 at 3:45 PM
	Abbott and the Abbott Fund Donate $1 Million to Support Hurricane Harvey Relief Efforts finance.yahoo.com - August 29 at 3:45 PM
	Abbott and the Abbott Fund Donate $1 Million to Support Hurricane Harvey Relief Efforts finance.yahoo.com - August 29 at 3:45 PM
	FDA Approves Abbott Heart Device, Stock Rises - TheStreet.com www.thestreet.com - August 28 at 8:37 PM
	Technical Snapshots for These Medical Equipment Stocks -- Abbott Labs, Boston ... www.prnewswire.com - August 28 at 3:34 PM
	Abbott Introduces HeartMate 3 Left Ventricular Assist System - the Latest Milestone In Therapy For Advanced Heart Failure Patients finance.yahoo.com - August 28 at 3:34 PM
	The Top 5 Healthcare Dividend Stocks Today seekingalpha.com - August 23 at 10:11 PM
	Abbott Laboratories – Value Analysis (NYSE:ABT) : August 23, 2017 finance.yahoo.com - August 23 at 10:10 PM
	Abbott Laboratories breached its 50 day moving average in a Bullish Manner : ABT-US : August 23, 2017 finance.yahoo.com - August 23 at 3:21 PM